Filing Flows › Neurocrine Biosciences (NBIX) › R&D spending
Neurocrine Biosciences (NBIX) R&D spending by quarter
Neurocrine Biosciences' R&D spending was $352M in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 6 quarters it ranged from $244M (Q2 2025) to $352M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $352M | +8% | +41% |
| Q2 2026 | $327M | +27% | +34% |
| Q4 2025 | $258M | +3% | — |
| Q3 2025 | $250M | +2% | — |
| Q2 2025 | $244M | -7% | — |
| Q1 2025 | $263M | — | — |
Q3 2026 at a glance
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neurocrine Biosciences' R&D spending?
Neurocrine Biosciences' R&D spending was $352M in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has Neurocrine Biosciences' R&D spending changed?
Over the last 6 quarters it ranged from $244M (Q2 2025) to $352M (Q3 2026).
Q3 2026 results → · How Neurocrine Biosciences makes money →